Efficacy and Safety Evaluation of 177Lu-FAP-2286 in Advanced Lung Cancer Treatment
Study Overview
The study aimed to assess the effectiveness and safety of peptide-targeted radionuclide therapy (PTRT) with 177Lu-FAP-2286 in patients with advanced lung cancer.
Results and Findings
Short-term efficacy assessment showed 44% of patients had a partial metabolic response, 33.3% had stable metabolic disease, and 22.22% had progressive metabolic disease. The highest metabolic response after treatment reached 66.89%, with an overall response rate of 77.78%. The median overall survival and progression-free survival (PFS) were 10 months and 6 months, respectively. Patients experienced improvements in overall health status, symptom response, and quality of life after treatment. Notably, dyspnea and cancer-related pain symptoms showed the most significant improvements. No grade III/IV toxicity events were observed during the follow-up period, and fibrinogen levels decreased significantly after treatment.
Conclusion
177Lu-FAP-2286 shows potential as a viable PTRT option for patients with advanced lung cancer.
